366 related articles for article (PubMed ID: 32628531)
1. Clinical Benefits, Harms, and Cost-Effectiveness of Breast Cancer Screening for Survivors of Childhood Cancer Treated With Chest Radiation : A Comparative Modeling Study.
Yeh JM; Lowry KP; Schechter CB; Diller LR; Alagoz O; Armstrong GT; Hampton JM; Leisenring W; Liu Q; Mandelblatt JS; Miglioretti DL; Moskowitz CS; Oeffinger KC; Trentham-Dietz A; Stout NK
Ann Intern Med; 2020 Sep; 173(5):331-341. PubMed ID: 32628531
[TBL] [Abstract][Full Text] [Related]
2. Breast Cancer Screening Among Childhood Cancer Survivors Treated Without Chest Radiation: Clinical Benefits and Cost-Effectiveness.
Yeh JM; Lowry KP; Schechter CB; Diller LR; O'Brien G; Alagoz O; Armstrong GT; Hampton JM; Hudson MM; Leisenring W; Liu Q; Mandelblatt JS; Miglioretti DL; Moskowitz CS; Nathan PC; Neglia JP; Oeffinger KC; Trentham-Dietz A; Stout NK
J Natl Cancer Inst; 2022 Feb; 114(2):235-244. PubMed ID: 34324686
[TBL] [Abstract][Full Text] [Related]
3. Tailoring Breast Cancer Screening Intervals by Breast Density and Risk for Women Aged 50 Years or Older: Collaborative Modeling of Screening Outcomes.
Trentham-Dietz A; Kerlikowske K; Stout NK; Miglioretti DL; Schechter CB; Ergun MA; van den Broek JJ; Alagoz O; Sprague BL; van Ravesteyn NT; Near AM; Gangnon RE; Hampton JM; Chandler Y; de Koning HJ; Mandelblatt JS; Tosteson AN;
Ann Intern Med; 2016 Nov; 165(10):700-712. PubMed ID: 27548583
[TBL] [Abstract][Full Text] [Related]
4. Personalizing mammography by breast density and other risk factors for breast cancer: analysis of health benefits and cost-effectiveness.
Schousboe JT; Kerlikowske K; Loh A; Cummings SR
Ann Intern Med; 2011 Jul; 155(1):10-20. PubMed ID: 21727289
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of Breast Cancer Screening With Magnetic Resonance Imaging for Women at Familial Risk.
Geuzinge HA; Obdeijn IM; Rutgers EJT; Saadatmand S; Mann RM; Oosterwijk JC; Tollenaar RAEM; de Roy van Zuidewijn DBW; Lobbes MBI; van 't Riet M; Hooning MJ; Ausems MGEM; Loo CE; Wesseling J; Luiten EJT; Zonderland HM; Verhoef C; Heijnsdijk EAM; Tilanus-Linthorst MMA; de Koning HJ;
JAMA Oncol; 2020 Sep; 6(9):1381-1389. PubMed ID: 32729887
[TBL] [Abstract][Full Text] [Related]
6. Benefits, harms, and cost-effectiveness of supplemental ultrasonography screening for women with dense breasts.
Sprague BL; Stout NK; Schechter C; van Ravesteyn NT; Cevik M; Alagoz O; Lee CI; van den Broek JJ; Miglioretti DL; Mandelblatt JS; de Koning HJ; Kerlikowske K; Lehman CD; Tosteson AN
Ann Intern Med; 2015 Feb; 162(3):157-66. PubMed ID: 25486550
[TBL] [Abstract][Full Text] [Related]
7. Breast Cancer Screening Strategies for Women With ATM, CHEK2, and PALB2 Pathogenic Variants: A Comparative Modeling Analysis.
Lowry KP; Geuzinge HA; Stout NK; Alagoz O; Hampton J; Kerlikowske K; de Koning HJ; Miglioretti DL; van Ravesteyn NT; Schechter C; Sprague BL; Tosteson ANA; Trentham-Dietz A; Weaver D; Yaffe MJ; Yeh JM; Couch FJ; Hu C; Kraft P; Polley EC; Mandelblatt JS; Kurian AW; Robson ME;
JAMA Oncol; 2022 Apr; 8(4):587-596. PubMed ID: 35175286
[TBL] [Abstract][Full Text] [Related]
8. Tipping the balance of benefits and harms to favor screening mammography starting at age 40 years: a comparative modeling study of risk.
van Ravesteyn NT; Miglioretti DL; Stout NK; Lee SJ; Schechter CB; Buist DS; Huang H; Heijnsdijk EA; Trentham-Dietz A; Alagoz O; Near AM; Kerlikowske K; Nelson HD; Mandelblatt JS; de Koning HJ
Ann Intern Med; 2012 May; 156(9):609-17. PubMed ID: 22547470
[TBL] [Abstract][Full Text] [Related]
9. Collaborative Modeling of the Benefits and Harms Associated With Different U.S. Breast Cancer Screening Strategies.
Mandelblatt JS; Stout NK; Schechter CB; van den Broek JJ; Miglioretti DL; Krapcho M; Trentham-Dietz A; Munoz D; Lee SJ; Berry DA; van Ravesteyn NT; Alagoz O; Kerlikowske K; Tosteson AN; Near AM; Hoeffken A; Chang Y; Heijnsdijk EA; Chisholm G; Huang X; Huang H; Ergun MA; Gangnon R; Sprague BL; Plevritis S; Feuer E; de Koning HJ; Cronin KA
Ann Intern Med; 2016 Feb; 164(4):215-25. PubMed ID: 26756606
[TBL] [Abstract][Full Text] [Related]
10. Health Benefits and Cost-Effectiveness of Children's Oncology Group Breast Cancer Screening Guidelines for Chest-Irradiated Hodgkin Lymphoma Survivors.
Wong FL; Lee JM; Leisenring WM; Neglia JP; Howell RM; Smith SA; Oeffinger KC; Moskowitz CS; Henderson TO; Mertens A; Nathan PC; Yasui Y; Landier W; Armstrong GT; Robison LL; Bhatia S
J Clin Oncol; 2023 Feb; 41(5):1046-1058. PubMed ID: 36265088
[TBL] [Abstract][Full Text] [Related]
11. Should women with a BRCA1/2 mutation aged 60 and older be offered intensified breast cancer screening? - A cost-effectiveness analysis.
Phi XA; Greuter MJW; Obdeijn IM; Oosterwijk JC; Feenstra TL; Houssami N; de Bock GH
Breast; 2019 Jun; 45():82-88. PubMed ID: 30904701
[TBL] [Abstract][Full Text] [Related]
12. Cost-Utility of Early Breast Cancer Surveillance in Survivors of Thoracic Radiation-Treated Adolescent Hodgkin Lymphoma.
Furzer J; Tessier L; Hodgson D; Cotton C; Nathan PC; Gupta S; Pechlivanoglou P
J Natl Cancer Inst; 2020 Jan; 112(1):63-70. PubMed ID: 31070751
[TBL] [Abstract][Full Text] [Related]
13. Cost-Effectiveness of Screening Mammography Beyond Age 75 Years : A Cost-Effectiveness Analysis.
Schousboe JT; Sprague BL; Abraham L; O'Meara ES; Onega T; Advani S; Henderson LM; Wernli KJ; Zhang D; Miglioretti DL; Braithwaite D; Kerlikowske K
Ann Intern Med; 2022 Jan; 175(1):11-19. PubMed ID: 34807717
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of alternating magnetic resonance imaging and digital mammography screening in BRCA1 and BRCA2 gene mutation carriers.
Cott Chubiz JE; Lee JM; Gilmore ME; Kong CY; Lowry KP; Halpern EF; McMahon PM; Ryan PD; Gazelle GS
Cancer; 2013 Mar; 119(6):1266-76. PubMed ID: 23184400
[TBL] [Abstract][Full Text] [Related]
15. Benefits, harms, and costs for breast cancer screening after US implementation of digital mammography.
Stout NK; Lee SJ; Schechter CB; Kerlikowske K; Alagoz O; Berry D; Buist DS; Cevik M; Chisholm G; de Koning HJ; Huang H; Hubbard RA; Miglioretti DL; Munsell MF; Trentham-Dietz A; van Ravesteyn NT; Tosteson AN; Mandelblatt JS
J Natl Cancer Inst; 2014 Jun; 106(6):dju092. PubMed ID: 24872543
[TBL] [Abstract][Full Text] [Related]
16. Breast MRI screening for average-risk women: A monte carlo simulation cost-benefit analysis.
Mango VL; Goel A; Mema E; Kwak E; Ha R
J Magn Reson Imaging; 2019 Jun; 49(7):e216-e221. PubMed ID: 30632645
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of MRI for breast cancer screening in BRCA1/2 mutation carriers.
Pataky R; Armstrong L; Chia S; Coldman AJ; Kim-Sing C; McGillivray B; Scott J; Wilson CM; Peacock S
BMC Cancer; 2013 Jul; 13():339. PubMed ID: 23837641
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of screening BRCA1/2 mutation carriers with breast magnetic resonance imaging.
Plevritis SK; Kurian AW; Sigal BM; Daniel BL; Ikeda DM; Stockdale FE; Garber AM
JAMA; 2006 May; 295(20):2374-84. PubMed ID: 16720823
[TBL] [Abstract][Full Text] [Related]
19. Insights Into Breast Cancer Screening: A Computer Simulation of Two Contemporary Screening Strategies.
Carter KJ; Castro F; Morcos RN
AJR Am J Roentgenol; 2018 Mar; 210(3):564-571. PubMed ID: 29323554
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
